Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $11.72 and last traded at $11.07, with a volume of 4600 shares traded. The stock had previously closed at $10.60.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on PHAR shares. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th.
Read Our Latest Report on Pharming Group
Pharming Group Price Performance
The company has a market cap of $827.26 million, a PE ratio of -46.77 and a beta of -0.08. The business has a 50 day moving average of $9.14 and a 200 day moving average of $8.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $79.09 million during the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts predict that Pharming Group will post -0.2 EPS for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
